A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.

Mazziotta F, Martin LE, Egan DN, Bar M, Kinsella S, Paulson KG, Voillet V, Lahman MC, Hunter D, Schmitt TM, Duerkopp N, Yeung CCS, Tang TH, Gottardo R, Asano Y, Wilcox EC, Lee B, Zhang T, Lopedote P, Penter L, Wu CJ, Milano F, Greenberg PD, Chapuis AG

Open source

DOI: 10.1038/s41467-025-60394-0
Published: 2025 Jun 5
Container: Nature communications
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41467-025-60394-0,
  title = {A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.},
  author = {Mazziotta F and Martin LE and Egan DN and Bar M and Kinsella S and Paulson KG and Voillet V and Lahman MC and Hunter D and Schmitt TM and Duerkopp N and Yeung CCS and Tang TH and Gottardo R and Asano Y and Wilcox EC and Lee B and Zhang T and Lopedote P and Penter L and Wu CJ and Milano F and Greenberg PD and Chapuis AG},
  year = {2025},
  journal = {Nature communications},
  doi = {10.1038/s41467-025-60394-0},
  url = {https://doi.org/10.1038/s41467-025-60394-0}
}

RIS

TY  - JOUR
TI  - A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.
AU  - Mazziotta F
AU  - Martin LE
AU  - Egan DN
AU  - Bar M
AU  - Kinsella S
AU  - Paulson KG
AU  - Voillet V
AU  - Lahman MC
AU  - Hunter D
AU  - Schmitt TM
AU  - Duerkopp N
AU  - Yeung CCS
AU  - Tang TH
AU  - Gottardo R
AU  - Asano Y
AU  - Wilcox EC
AU  - Lee B
AU  - Zhang T
AU  - Lopedote P
AU  - Penter L
AU  - Wu CJ
AU  - Milano F
AU  - Greenberg PD
AU  - Chapuis AG
PY  - 2025
JO  - Nature communications
DO  - 10.1038/s41467-025-60394-0
UR  - https://doi.org/10.1038/s41467-025-60394-0
ER  -

APA

F, M., LE, M., DN, E., M, B., S, K., KG, P., V, V., MC, L., D, H., TM, S., N, D., CCS, Y., TH, T., R, G., Y, A., EC, W., B, L., T, Z., P, L., L, P., CJ, W., F, M., PD, G., & AG, C. (2025). A phase I/II trial of WT1-specific TCR gene therapy for patients with acute myeloid leukemia and active disease post-allogeneic hematopoietic cell transplantation: skewing towards NK-like phenotype impairs T cell function and persistence.. Nature communications. https://doi.org/10.1038/s41467-025-60394-0

Source records

pubmed · retrieved 2026-09-25T22:10:26.904Z